KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) FCF Margin (2016 - 2026)

Pacific Biosciences Of California has reported FCF Margin over the past 16 years, most recently at 44.64% for Q4 2025.

  • For Q4 2025, FCF Margin rose 3762.0% year-over-year to 44.64%; the TTM value through Dec 2025 reached 71.2%, up 6661.0%, while the annual FY2025 figure was 71.2%, 6661.0% up from the prior year.
  • FCF Margin for Q4 2025 was 44.64% at Pacific Biosciences Of California, up from 48.44% in the prior quarter.
  • Over five years, FCF Margin peaked at 44.64% in Q4 2025 and troughed at 252.99% in Q1 2023.
  • A 5-year average of 132.78% and a median of 111.78% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: crashed -56347bps in 2021 and later surged 13725bps in 2023.
  • Year by year, FCF Margin stood at 95.92% in 2021, then plummeted by -150bps to 239.35% in 2022, then skyrocketed by 57bps to 102.1% in 2023, then grew by 19bps to 82.26% in 2024, then soared by 46bps to 44.64% in 2025.
  • Business Quant data shows FCF Margin for PACB at 44.64% in Q4 2025, 48.44% in Q3 2025, and 75.26% in Q2 2025.